LISINOPRIL AND HYDROCHLOROTHIAZIDE description, usages, side effects, indications, overdosage, supplying and lots more!

Menu
Search

LISINOPRIL AND HYDROCHLOROTHIAZIDE

Dispensing Solutions, Inc.

LISINOPRIL AND HYDROCHLOROTHIAZIDE USP


FULL PRESCRIBING INFORMATION: CONTENTS*




FULL PRESCRIBING INFORMATION

10 mg/12.5 mg, 20 mg/12.5 mg and 20 mg/25 mg

Rx only

USE IN PREGNANCY

When used in pregnancy during the second and third trimesters, ACE inhibitors can cause injury and even death to the developing fetus. When pregnancy is detected, lisinopril and hydrochlorothiazide tablets should be discontinued as soon as possible. See  WARNINGS, Pregnancy, Lisinopril, Fetal/Neonatal Morbidity and Mortality.

LISINOPRIL AND HYDROCHLOROTHIAZIDE DESCRIPTION

Lisinopril and hydrochlorothiazide tablets combines an angiotensin converting enzyme inhibitor, lisinopril, and a diuretic, hydrochlorothiazide.

Lisinopril, a synthetic peptide derivative, is an oral long-acting angiotensin converting enzyme inhibitor. It is chemically described as (S)-1-[N2-(1-carboxy-3-phenylpropyl)-L-lysyl]-L-proline dihydrate. Its empirical formula is C21H31N3O5•2H2O and its structural formula is:

LISINOPRIL AND HYDROCHLOROTHIAZIDE

Lisinopril is a white to off-white, crystalline powder, with a molecular weight of 441.52. It is soluble in water, sparingly soluble in methanol, and practically insoluble in ethanol.

Hydrochlorothiazide is 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Its empirical formula is C7H8ClN3O4S2 and its structural formula is:

LISINOPRIL AND HYDROCHLOROTHIAZIDE

Hydrochlorothiazide is a white, or practically white, crystalline powder with a molecular weight of 297.73, which is slightly soluble in water, but freely soluble in sodium hydroxide solution.

Lisinopril and hydrochlorothiazide tablets are available for oral use in three tablet combinations of lisinopril with hydrochlorothiazide: lisinopril and hydrochlorothiazide tablets 10 mg/12.5 mg, containing 10 mg lisinopril and 12.5 mg hydrochlorothiazide, lisinopril and hydrochlorothiazide tablets 20 mg/12.5 mg, containing 20 mg lisinopril and 12.5 mg hydrochlorothiazide and lisinopril and hydrochlorothiazide tablets 20 mg/25 mg, containing 20 mg lisinopril and 25 mg hydrochlorothiazide.

Inactive ingredients are dibasic calcium phosphate, magnesium stearate, mannitol, pregelatinized starch and starch. Lisinopril and hydrochlorothiazide tablets 10 mg/12.5 mg also contains FD and C Blue No. 2 Aluminum Lake. Lisinopril and hydrochlorothiazide tablets 20 mg/12.5 mg also contains yellow iron oxide and lisinopril and hydrochlorothiazide tablets 20 mg/25 mg also contain red iron oxide.

LISINOPRIL AND HYDROCHLOROTHIAZIDE INDICATIONS AND USAGE

Lisinopril and hydrochlorothiazide tablets are indicated for the treatment of hypertension.

These fixed-dose combinations are not indicated for initial therapy (see  DOSAGE AND   ADMINISTRATION).

In using lisinopril and hydrochlorothiazide tablets, consideration should be given to the fact that an angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that lisinopril does not have a similar risk. (See  WARNINGS.)

In considering use of lisinopril and hydrochlorothiazide tablets, it should be noted that Black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-Blacks. (See  WARNINGS, Head and Neck Angioedema.)

LISINOPRIL AND HYDROCHLOROTHIAZIDE CONTRAINDICATIONS

Lisinopril and hydrochlorothiazide is contraindicated in patients who are hypersensitive to any component of this product and in patients with a history of angioedema related to previous treatment with an angiotensin converting enzyme inhibitor and in patients with hereditary or idiopathic angioedema. Because of the hydrochlorothiazide component, this product is contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs.

LISINOPRIL AND HYDROCHLOROTHIAZIDE ADVERSE REACTIONS

Lisinopril and hydrochlorothiazide has been evaluated for safety in 930 patients, including 100 patients treated for 50 weeks or more.

In clinical trials with lisinopril and hydrochlorothiazide no adverse experiences peculiar to this combination drug have been observed. Adverse experiences that have occurred have been limited to those that have been previously reported with lisinopril or hydrochlorothiazide.

The most frequent clinical adverse experiences in controlled trials (including open label extensions) with any combination of lisinopril and hydrochlorothiazide were: dizziness (7.5 percent), headache (5.2 percent), cough (3.9 percent), fatigue (3.7 percent) and orthostatic effects (3.2 percent), all of which were more common than in placebo-treated patients. Generally, adverse experiences were mild and transient in nature; but see  WARNINGSregarding angioedema and excessive hypotension or syncope. Discontinuation of therapy due to adverse effects was required in 4.4 percent of patients, principally because of dizziness, cough, fatigue and muscle cramps.

Adverse experiences occurring in greater than one percent of patients treated with lisinopril plus hydrochlorothiazide in controlled clinical trials are shown below.

Percent of Patients in Controlled Studies


Lisinopril-Hydrochlorothiazide
(n=930)
Incidence
(discontinuation)
Placebo
(n=207)
Incidence
Dizziness
7.5 (.8)
1.9
Headache
5.2 (0.3)
19
Cough
3.9 (0.6)
1.0
Fatigue
3.7 (0.4)
1.0
Orthostatic Effects
3.2 (0.1)
1.0
Diarrhea
2.5 (0.2)
2.4
Nausea
2.2 (0.1)
2.4
Upper Respiratory Infection
2.2 (0.0)
0.0
Muscle Cramps
2.0 (0.4)
0.5
Asthenia
1.8 (0.2)
1.0
Parasthesia
1.5 (0.1)
0.0
Hypotension
1.4 (0.3)
0.5
Vomiting
1.4 (0.1)
0.5
Dyspepsia
1.3 (0.0)
0.0
Rash
1.2 (0.1)
0.5
Impotence
1.2 (0.3)
0.0
Body as a Whole:CardiovascularDigestiveMusculoskeletalNervous/PsychiatricRespiratorySkinSpecial SensesUrogenital

Angioedema

Hypotension

CoughCough


Clinical Laboratory Test Findings

Serum Electrolytes: See  PRECAUTIONS.

Creatinine, Blood Urea Nitrogen: Minor reversible increases in blood urea nitrogen and serum creatinine were observed in patients with essential hypertension treated with lisinopril and hydrochlorothiazide. More marked increases have also been reported and were more likely to occur in patients with renal artery stenosis. (See  PRECAUTIONS.)

Serum Uric Acid, Glucose, Magnesium, Cholesterol, Triglycerides and Calcium: See  PRECAUTIONS.

OVERDOSAGE

No specific information is available on the treatment of overdosage with lisinopril and hydrochlorothiazide. Treatment is symptomatic and supportive. Therapy with lisinopril and hydrochlorothiazide should be discontinued and the patient observed closely. Suggested measures include induction of emesis and/or gastric lavage, and correction of dehydration, electrolyte imbalance and hypotension by established procedures.

Lisinopril

Following a single oral dose of 20 mg/kg, no lethality occurred in rats and death occurred in one of 20 mice receiving the same dose. The most likely manifestation of overdosage would be hypotension, for which the usual treatment would be intravenous infusion of normal saline solution.

Lisinopril can be removed by hemodialysis. (See  WARNINGS, Anaphylactoid reactions during membrane exposure.)

Hydrochlorothiazide

Oral administration of a single oral dose of 10 mg/kg to mice and rats was not lethal. The most common signs and symptoms observed are those caused by electrolyte depletion (hypokalemia, hypochloremia, hyponatremia) and dehydration resulting from excessive diuresis. If digitalis has also been administered, hypokalemia may accentuate cardiac arrhythmias.

LISINOPRIL AND HYDROCHLOROTHIAZIDE DOSAGE AND ADMINISTRATION

Lisinopril is an effective treatment of hypertension in once-daily doses of 10 to 80 mg, while hydrochlorothiazide is effective in doses of 12.5 to 50 mg. In clinical trials of lisinopril/hydrochlorothiazide combination therapy using lisinopril doses of 10 to 80 mg and hydrochlorothiazide doses of 6.25 to 50 mg, the antihypertensive response rates generally increased with increasing dose of either component.

The side effects (see  WARNINGS) of lisinopril are generally rare and apparently independent of dose; those of hydrochlorothiazide are a mixture of dose-dependent phenomena (primarily hypokalemia) and dose-independent phenomena (e.g., pancreatitis), the former much more common than the latter. Therapy with any combination of lisinopril and hydrochlorothiazide will be associated with both sets of dose-independent side effects, but addition of lisinopril in clinical trials blunted the hypokalemia normally seen with diuretics.

To minimize dose-independent side effects, it is usually appropriate to begin combination therapy only after a patient has failed to achieve the desired effect with monotherapy.

Dose Titration Guided by Clinical Effect

A patient whose blood pressure is not adequately controlled with either lisinopril or hydrochlorothiazide monotherapy may be switched to lisinopril and hydrochlorothiazide tablets 10 mg/12.5 mg or lisinopril and hydrochlorothiazide tablets 20 mg/12.5 mg. Further increases of either or both components could depend on clinical response. The hydrochlorothiazide dose should generally not be increased until 2-3 weeks have elapsed. Patients whose blood pressures are adequately controlled with 25 mg of daily hydrochlorothiazide, but who experience significant potassium loss with this regimen, may achieve similar or greater blood pressure control with less potassium loss if they are switched to lisinopril and hydrochlorothiazide tablets 10 mg/12.5 mg. Dosage higher than lisinopril 80 mg and hydrochlorothiazide  50 mg should not be used.

Replacement Therapy

The combination may be substituted for the titrated individual components.

Use in Renal Impairment

The usual regimens of therapy with lisinopril and hydrochlorothiazide tablets need not be adjusted as long as the patient's creatinine clearance is >30 mL/min/1.73 m2 (serum creatinine approximately (3 mg/dL or 265 µmol/L). In patients with more severe renal impairment, loop diuretics are preferred to thiazides, so lisinopril and hydrochlorothiazide tablets are not recommended (see  WARNINGS, Anaphylactoid reactions during membrane exposure).

HOW SUPPLIED

Lisinopril and Hydrochlorothiazide Tablets USP, 10 mg/12.5 mg are blue, hexagonal tablets, with "LL" debossed on one side and "B01" on other side.

They are supplied as follows:

NDC 68180-518-01 – 100’s bottle

NDC 68180-518-02 – 500’s bottle

Lisinopril and Hydrochlorothiazide Tablets USP, 20 mg/12.5 mg are yellow, round tablets, with "LL" debossed on one side and "B02" on other side.

They are supplied as follows:

NDC 68180-519-01 – 100’s bottle

NDC 68180-519-02 – 500’s bottle

Lisinopril and Hydrochlorothiazide Tablets USP, 20 mg/25 mg are peach, round tablets, with "LL" debossed on one side and "B03" on other side.

They are supplied as follows:

NDC 68180-520-01 – 100’s bottle

NDC 68180-520-02 – 500’s bottle

Storage

Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature]. Protect from excessive light and humidity.

Manufactured for:     

Lupin Pharmaceuticals, Inc.

Baltimore, Maryland 21202

United States

Manufactured by:       

Lupin Limited

Goa 403 722

INDIA

Or

Lupin Limited

Pithampur (M.P.) 454 775

INDIA

Revised: 15th April 2011                                                                   ID#: 224651

PRINCIPAL DISPLAY PANEL

LISINOPRIL AND HYDROCHLOROTHIAZIDE TABLETS USP

Rx Only

10 mg/12.5 mg

LISINOPRIL AND HYDROCHLOROTHIAZIDE

NDC 66336-0572-XX

Tablets

LISINOPRIL AND HYDROCHLOROTHIAZIDE

LISINOPRIL AND HYDROCHLOROTHIAZIDE TABLET

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:66336-572(NDC:68180-518)
Route of Administration ORAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
HYDROCHLOROTHIAZIDE HYDROCHLOROTHIAZIDE 12.5 mg
LISINOPRIL LISINOPRIL ANHYDROUS 10 mg

Inactive Ingredients

Ingredient Name Strength
ANHYDROUS DIBASIC CALCIUM PHOSPHATE
FD&C BLUE NO. 2
mannitol
STARCH, CORN
MAGNESIUM STEARATE
STARCH, PREGELATINIZED CORN

Product Characteristics

Color Size Imprint Code Shape
blue 7 mm LL;B01 HEXAGON (6 sided)

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:66336-572-90 90 in 1 BOTTLE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA077912 2006-10-02


PLEASE, BE CAREFUL!
Be sure to consult your doctor before taking any medication!
Copyright © 2014. drugs-library.com. All rights reserved. Information on drugs-library.com is provided for educational purposes only and is not to be used for medical advice, diagnosis or treatment.
Support info@drugs-library.com.